Caribou Biosciences (CRBU) Tax Provisions (2020 - 2021)
Caribou Biosciences' (CRBU) quarterly Tax Provisions came in at $321000.0 in Q4 2021, up 190.68% year-on-year from $110431.5 in Q4 2020, and up 190.68% on a QoQ basis from -$354000.0 in Q4 2020.
Caribou Biosciences (CRBU) Tax Provisions (2020 - 2021) Analysis & Trends
Caribou Biosciences (CRBU) has 2 years of Tax Provisions data on file, last reported at $321000.0 in Q4 2021.
- On a quarterly basis, Tax Provisions rose 190.68% year-over-year to $321000.0 in Q4 2021; TTM through Dec 2021 was $321000.0, a 117.65% increase from a year earlier, with the FY2025 full-year figure at -$550000.0, down 6011.11% from the prior year.
- Tax Provisions for Q4 2021 stood at $321000.0, up from -$354000.0 in the prior quarter.
- Over the last five years, Tax Provisions for CRBU reached as high as $321000.0 in Q4 2021 and fell as low as -$1.2 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 179.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Caribou Biosciences | 152.90 Mn | 35.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 321,000.00 |
| Dec 31, 2020 | -354,000.00 |
| Sep 30, 2020 | -213,000.00 |
| Jun 30, 2020 | -50,000.00 |
| Mar 31, 2020 | -1.20 Mn |